Table 2.

Impact of BM and use of PCI in 2 chemoimmunotherapy trials in extensive SCLC.

	Impower 133	Caspian
ICI	Atezolizumab	Durvalumab
Brain metastases (inclusion criteria)	Asymptomatic and treated	Asymptomatic or treated
Presence of brain metastases	8,5% Exp arm 8,9% Placebo arm	10,7% Experimental arm 14.8% Placebo arm
PCI	Both arms permitted	Only in control arm permitted
Frequency of PCI	10%	8%
Stratification for BM	yes	no
mOS (with BM)	8,5 mOS Experimental arm 9,7 mOS Placebo	11,7 mOS Experimental arm 8,8 mOS Placebo

ICI, Immune Checkpoint Inhibitor; BM, Brain Metastasis; mOS, median Overal Survival; PCI, Prophylactic Cranial Irradiation.